Modality
Multispecific
MOA
TYK2i
Target
Aβ
Pathway
PD-1/PD-L1
Urothelial Ca
Development Pipeline
Preclinical
May 2023
PreclinicalCurrent
NCT06909474
194 pts·Urothelial Ca
2023-05→TBD·Completed
194 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06909474 | Preclinical | Urothelial Ca | Completed | 194 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ |